Trials / Completed
CompletedNCT05139667
Evaluation of Mucoadhesive Tacrolimus Patch on Caspase-3 Inducing Apoptosis in Oral Lichen Planus
Evaluation of Mucoadhesive Tacrolimus Patch on Caspase-3 Inducing Apoptosis in Oral Lichen Planus ( A Randomized Controlled Clinical Trial With Immunohistochemical Analysis)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Ain Shams University · Academic / Other
- Sex
- All
- Age
- 25 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
tacrolimus has been widely used as an immunosuppressant. the objective of this study was to evaluate the clinical efficacy of tacrolimus 0.1 % in muco adhesive patch compared to tacrolimus or corticosteroids in paste forms for symptomatic oral lichen planus, and to investigate the effect of topical tacrolimus or corticosteroids on the expression of caspase-3 in oral lichen planus as an early marker of apoptosis using immunohistochemically analysis
Detailed description
thirty patients with erosive or atrophic OLP were randomly assigned into three equal groups to receive topical steroid ( triamcinolone acetonide 0.1%), four times per day ( Group 1), tacrolimus paste 0.1% four times per day ( Group 2) , and tacrolimus patch 2 times per day ( Group 3). all groups are given treatment for 8 weeks and 4 weeks follow up period without treatment. Photographs of the most severe lesion were taken ( marker lesion ) in each patient and analyzed for total ulcerative area (TUA), total atrophic area (TAA). patients were also assessed using clinical scores (CS) and visual analogue scale (VAS). pre treatment and post treatment specimens were immunohistochemically stained to detect expression of caspase-3.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Corticosteroid Topical | topical tacrolimus and corticosteroids |
Timeline
- Start date
- 2019-05-20
- Primary completion
- 2021-10-20
- Completion
- 2021-10-20
- First posted
- 2021-12-01
- Last updated
- 2021-12-01
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05139667. Inclusion in this directory is not an endorsement.